Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 ...
Advanced therapies, medicines bring new hope for pulmonary hypertension patients: Dr Manisha Mendiratta: Shardul Nautiyal, Mumbai Saturday, February 8, 2025, 08:00 Hrs [IST] Dr Ma ...
Gossamer Bio Inc. has released new data showing its inhaled kinase inhibitor, seralutinib, has long-lasting effects on ...
Seropositive rheumatoid arthritis may be protective against the development of PAH, based on results of Mendelian randomization analyses.
The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two ...
Safety of a Potential New Treatment to Manage Complications from Sickle Cell Disease Apr. 11, 2024 — A drug approved to treat pulmonary arterial hypertension may be effective at managing ...
The HYPERION study will be stopped early due to positive efficacy data from across the sotatercept clinical program.
Published in the Journal of the American Heart Association, the study showcases the potential of AI-powered heart sound ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback